GSK, Epix ink $1.2B deal
|
DEALS |
|||
|
WHO |
WITH |
WHAT |
SCOOP |
|
GlaxoSmithKline |
Epix Pharmaceuticals |
$1.2B development deal |
Glaxo gets access to a family of proteins called G-protein coupled receptors. |
|
Roche |
Halozyme Therapeutics |
$581 licensing deal |
Roche has licensed Halozyme Therapeutics' drug delivery technology, Enhanze. |
|
GlaxoSmithKline |
Domantis |
$454M buyout |
Glaxo is acquiring a leading developer of monoclonal antibodies. |
|
Genentech |
AC Immune |
$300M licensing deal |
AC Immune has been engaged in preclinical studies with a new therapy that has demonstrated an ability to make beta-amyloids soluble. |
|
Nycomed |
Durect |
$202M development deal |
The two will develop Posidur using Durect's delivery system. |
|
Indevus Pharmaceuticals |
Valera Pharmaceuticals |
$120M buyout |
The buyout gives Indevus control of Valera's work in urology and endicronology. |
|
PerkinElmer |
Evotec Technologies |
$30.47 acquisition |
Evotec Technologies provides systems for confocal imaging, cell handling, ultra-high throughput screening as well as image capture and cellular analysis software. |
|
Roche Holdings |
Xenon |
$51M development deal |
Roche gains an option to commercialize protein therapeutics targeting hemojuvelin as well as a licensing option for small molecule inhibitors of HJV. |
|
Pfizer |
Scripps Research Institute |
$20M development deal |
Pfizer will pay Scripps Research Institute $20 million a year for five years to help develop new therapies for diabetes, cancer, mental diseases and other conditions. |
|
Merck |
Idera |
Collaboration agreement |
Merck has struck a deal to put Idera's toll-like receptor agonists to work in its new vaccine programs for oncology, Alzheimer's and infectious diseases. |